Fangfang Pu, Yue Guo, Ming Li, Hong Zhu, Shijie Wang, Xi Shen, Miao He, Chengyu Huang, Fang He
Journal: Clinical interventions in aging 2018;12():1223-1231
PMID: 28848330
Yoghurt contains beneficial bacteria that are known modify the immune system in a way that can help to reduce upper respiratory tract infections (URTIs), such as flu. The aim of this randomised controlled study was to evaluate whether yoghurt supplemented with a probiotic strain known as Lactobacillus paracasei N1115 (N1115) could protect older adults from acute URTIs. 205 volunteers aged 45 years and over were randomly divided into two groups. Volunteers in the intervention group were given 300 ml of yoghurt supplemented with N1115 (3.6×107 CFU/ml) for 12 weeks, while those in the control group retained their normal diet without any probiotic supplementation. The incidence of URTIs and various immune markers were measured during the study. Compared to the control group, the number of people diagnosed with an acute URTI and the number of URTI events significantly decreased in the intervention group. The risk of URTI in the probiotic group was 55% that of the control group. The change in the percentage of the immune CD3+ cells in the intervention group was significantly higher than in the control group, but no significant differences were observed in the total protein, albumin, globulin, and prealbumin levels in both groups. The authors concluded that daily intake of yoghurt with selected probiotic strains such as N1115 can reduce the risk of URTIs in older adults. This effect may be due to the enhancement of T-cell immunity.
PURPOSE
To evaluate whether yogurt supplemented with a probiotic strain could protect middle-aged and elderly people from acute upper respiratory tract infections (URTI) using a randomized, blank-controlled, parallel-group design.
PATIENTS AND METHODS
Two hundred and five volunteers aged ≥45 years were randomly divided into two groups. The subjects in the intervention group were orally administered 300 mL/d of yogurt supplemented with a probiotic strain, N1115 (N1115), 3.6×10 CFU/mL for 12 weeks, while those in the control group retained their normal diet without any probiotic supplementation. The primary outcome was the incidence of URTI, and changes in serum protein, immunoglobulins, and the profiles of the T-lymphocyte subsets (total T-cells [CD3], T-helper cells [CD4], and T-cytotoxic-suppressor cells [CD8]) during the intervention were the secondary outcomes.
RESULTS
Compared to the control group, the number of persons diagnosed with an acute URTI and the number of URTI events significantly decreased in the intervention group (=0.038, =0.030, respectively). The risk of URTI in the intervention group was evaluated as 55% of that in the control group (relative risk =0.55, 95% CI: 0.307-0.969). The change in the percentage of CD3 cells in the intervention group was significantly higher than in the control group (=0.038). However, no significant differences were observed in the total protein, albumin, globulin, and prealbumin levels in both groups (>0.05).
CONCLUSION
The study suggested that yogurt with selected probiotic strains such as N1115 may reduce the risk of acute upper tract infections in the elderly. The enhancement of the T-cell-mediated natural immune defense might be one of the important underlying mechanisms for probiotics to express their anti-infective effects.
Full Text Sources:
Medical:
Other Literature Sources:
Research Materials:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.